| scholarly article | Q13442814 |
| P50 | author | Douglas Richman | Q5301927 |
| John Coffin | Q6226532 | ||
| David M. Margolis | Q37380199 | ||
| Mary Kearney | Q55274692 | ||
| Manoj K Tripathy | Q57426104 | ||
| Joseph J Eron | Q87874621 | ||
| JoAnn D Kuruc | Q106614334 | ||
| Matthew C Strain | Q114718153 | ||
| P2093 | author name string | Kevin R Robertson | |
| Daria J Hazuda | |||
| Ronald J Bosch | |||
| Elizabeth M Anderson | |||
| Nancy M Archin | |||
| Angela D Kashuba | |||
| Amanda M Crooks | |||
| Kuo-Hsiung Yang | |||
| Noelle P Dahl | |||
| Rosalie Bateson | |||
| P2860 | cites work | The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. | Q24525309 |
| Eradication of HIV from the brain: reasons for pause | Q24612874 | ||
| Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy | Q28253761 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors | Q33926864 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| The survival benefits of AIDS treatment in the United States | Q34533291 | ||
| Highly precise measurement of HIV DNA by droplet digital PCR. | Q34661612 | ||
| Histone deacetylase inhibitors and HIV latency | Q34816844 | ||
| Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. | Q35845347 | ||
| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
| A novel PCR assay for quantification of HIV-1 RNA. | Q36827196 | ||
| New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma | Q36891848 | ||
| Dilution assay statistics | Q37073320 | ||
| Comparison of three nonradioisotopic polymerase chain reaction-based methods for detection of human immunodeficiency virus type 1 | Q37118589 | ||
| Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. | Q37119662 | ||
| A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression | Q37192141 | ||
| Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors | Q37257484 | ||
| Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs | Q37273652 | ||
| Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells | Q37393518 | ||
| Clinical studies of histone deacetylase inhibitors. | Q37512917 | ||
| Combined approaches for HIV cure | Q37664312 | ||
| Mechanisms of HIV latency: an emerging picture of complexity | Q37738147 | ||
| Control of HIV latency by epigenetic and non-epigenetic mechanisms | Q37972643 | ||
| Reactivation of latent HIV by histone deacetylase inhibitors. | Q38091753 | ||
| Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials | Q38096822 | ||
| Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription | Q39173861 | ||
| NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation | Q42128724 | ||
| TaqMan RT-PCR and VERSANT HIV-1 RNA 3.0 (bDNA) assay Quantification of HIV-1 RNA viral load in breast milk | Q44855777 | ||
| High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum | Q46536021 | ||
| A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer | Q79405028 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 728-735 | |
| P577 | publication date | 2014-03-11 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat | |
| P478 | volume | 210 |
| Q38754318 | "We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry |
| Q38919964 | A CRISPR Approach for Reactivating Latent HIV-1. |
| Q36353497 | A Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism |
| Q36736780 | A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy. |
| Q36250921 | Activation and lysis of human CD4 cells latently infected with HIV-1 |
| Q28544949 | Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy |
| Q40860152 | Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients |
| Q36737063 | Advances and hope for perinatal HIV remission and cure in children and adolescents |
| Q91711853 | An Analytically and Diagnostically Sensitive RNA Extraction and RT-qPCR Protocol for Peripheral Blood Mononuclear Cells |
| Q26853069 | Animal models in HIV cure research |
| Q40187580 | Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. |
| Q38812544 | Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells |
| Q90545813 | Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection |
| Q89026543 | Associations between HIV-1 DNA copy number, proviral transcriptional activity, and plasma viremia in individuals off or on suppressive antiretroviral therapy |
| Q28081427 | Bioinformatics and HIV latency |
| Q37260309 | Broad activation of latent HIV-1 in vivo |
| Q34180174 | Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice |
| Q53822439 | CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. |
| Q36675297 | CRISPR-mediated Activation of Latent HIV-1 Expression |
| Q38527822 | Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells? |
| Q26781511 | Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs |
| Q63727608 | Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals |
| Q95355768 | Chromatin Regulation and the Histone Code in HIV Latency |
| Q40091545 | Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. |
| Q39361321 | Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial |
| Q47564917 | Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency |
| Q40150928 | Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency. |
| Q38973362 | Current views on HIV-1 latency, persistence, and cure. |
| Q57425149 | Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design |
| Q36596027 | Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals |
| Q55455666 | Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. |
| Q37030360 | Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. |
| Q34596417 | Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques |
| Q28540858 | Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques |
| Q36644877 | Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy |
| Q38977425 | Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection |
| Q35252186 | Eradicating HIV-1 infection: seeking to clear a persistent pathogen |
| Q92494889 | Eradication of Human Immunodeficiency Virus Type-1 (HIV-1)-Infected Cells |
| Q40056964 | Evaluation of the innate immune modulator acitretin as a strategy to clear the HIV reservoir |
| Q35720063 | Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. |
| Q91176638 | Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation |
| Q38256237 | Finding a cure for human immunodeficiency virus-1 infection |
| Q34363988 | Framing expectations in early HIV cure research |
| Q57201701 | Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals |
| Q35612053 | Genome editing strategies: potential tools for eradicating HIV-1/AIDS. |
| Q40080802 | HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal |
| Q35680431 | HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission |
| Q38271132 | HIV eradication: combinatorial approaches to activate latent viruses |
| Q52680785 | HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. |
| Q54214251 | HIV latency reversing agents act through Tat post translational modifications. |
| Q92819446 | HIV-1 CRF01_AE subtype and HIV-1 DNA level among patients with chronic HIV-1 infection: a correlation study |
| Q38675631 | HIV-1 Eradication: Early Trials (and Tribulations). |
| Q35973632 | HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses |
| Q57039737 | HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals |
| Q92857802 | Have Cells Harboring the HIV Reservoir Been Immunoedited? |
| Q33817708 | High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay |
| Q36037844 | Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation |
| Q40154908 | Identification of benzazole compounds that induce HIV-1 transcription. |
| Q64990626 | Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency. |
| Q92136409 | Impact of Myeloid Reservoirs in HIV Cure Trials |
| Q93186350 | Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues |
| Q36523946 | In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors |
| Q91711883 | In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial |
| Q39749215 | In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection |
| Q92109292 | In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals |
| Q47153987 | Innovations in the quantitative virus outgrowth assay and its use in clinical trials. |
| Q89685622 | Integrated assessment of viral transcription, antigen presentation, and CD8+ T cell function reveal multiple limitations of class I selective HDACi during HIV-1 latency reversal |
| Q58598654 | Interferon-α Enhances NK Cell Function and the Suppressive Capacity of HIV-specific CD8+ T Cells |
| Q40120304 | Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency |
| Q37522861 | Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo |
| Q40597173 | Kinetics of HIV-1 Latency Reversal Quantified on the Single-Cell Level Using a Novel Flow-Based Technique |
| Q52313087 | Latent HIV dynamics and implications for sustained viral suppression in the absence of antiretroviral therapy. |
| Q36030989 | Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions |
| Q59354583 | Lysine-specific demethylase 1 cooperates with BRAF-histone deacetylase complex 80 to enhance HIV-1 Tat-mediated transactivation |
| Q26795463 | Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 |
| Q52695029 | Maraviroc is associated with latent HIV-1 reactivation through NF-κB activation in resting CD4+ T cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. |
| Q33627182 | Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals |
| Q38682297 | Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies |
| Q92134571 | Measuring the Success of HIV-1 Cure Strategies |
| Q38458190 | Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency |
| Q35819184 | Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells |
| Q36515063 | Molecular mechanisms of HIV latency |
| Q37695602 | Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency |
| Q59359574 | Nanotechnology approaches to eradicating HIV reservoirs |
| Q58862085 | Natural product-derived compounds in HIV suppression, remission, and eradication strategies |
| Q37177251 | Negative Feedback Regulation of HIV-1 by Gene Editing Strategy |
| Q45067800 | New Drugs in the Pipeline for the Treatment of HIV: a Review |
| Q38692205 | New challenges in therapeutic vaccines against HIV infection. |
| Q40289284 | No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy |
| Q39140209 | Novel AIDS therapies based on gene editing |
| Q52816327 | Novel Latency Reversal Agents for HIV-1 Cure. |
| Q38915896 | Novel immunological strategies for HIV-1 eradication |
| Q28079455 | Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents |
| Q38773102 | Paediatric HIV infection: the potential for cure |
| Q38958099 | Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial |
| Q59361053 | Peering into the HIV reservoir |
| Q98292337 | Pharmaceutical Approaches to HIV Treatment and Prevention |
| Q102144611 | Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo |
| Q59132651 | Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3 |
| Q90002680 | Precise and accurate power of the rank-sum test for a continuous outcome |
| Q39599213 | Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size |
| Q34869380 | Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium |
| Q40523607 | Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay |
| Q41918740 | Quiescence promotes latent HIV infection and resistance to reactivation from latency with histone deacetylase inhibitors |
| Q40069803 | Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. |
| Q40192992 | Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. |
| Q92860935 | Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells |
| Q30490742 | Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations |
| Q38667392 | SLDAssay: A software package and web tool for analyzing limiting dilution assays |
| Q37098390 | Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain |
| Q36525896 | Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. |
| Q52674721 | Sex Differences in HIV Infection. |
| Q36538827 | Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal |
| Q35002986 | Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo |
| Q57789788 | Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal |
| Q39237000 | The Alphabet Soup of HIV Reservoir Markers |
| Q36790027 | The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb |
| Q35778783 | The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo |
| Q92881205 | The Impact of Cellular Proliferation on the HIV-1 Reservoir |
| Q37144949 | The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function |
| Q47390378 | The doctor's dilemma and vaccine therapy for HIV. |
| Q38926320 | The therapeutic potential of epigenetic manipulation during infectious diseases. |
| Q90474772 | Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed |
| Q36515149 | Towards HIV-1 remission: potential roles for broadly neutralizing antibodies |
| Q38369541 | Towards an HIV-1 cure: measuring the latent reservoir |
| Q89709142 | Transcriptional profiling indicates cAMP-driven reversal of HIV latency in monocytes occurs via transcription factor SP-1 |
| Q35009744 | Translational challenges in targeting latent HIV infection and the CNS reservoir problem |
| Q38982212 | Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid |
| Q50032569 | Use of 'eradication' in HIV cure-related research: a public health debate |
| Q28077662 | Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research |
| Q90035728 | Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1 |
| Q58758736 | Variation in the Untranslated Genome and Susceptibility to Infections |
| Q40084640 | Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells |
Search more.